Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
MODERNA, INC. |
Real-time Estimate
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 79.02 USD | -1.96% | +1.51% | -56.09% | |
| 03:00pm | US sets policy to seize government-funded drug patents if price deemed too high | RE |
| 02:00pm | Transcript : Moderna, Inc. - Special Call | CI |
Financials (USD)
| Sales 2023 * | 6.49B | Sales 2024 * | 4.49B | Capitalization | 30.73B |
|---|---|---|---|---|---|
| Net income 2023 * | -5.42B | Net income 2024 * | -2.33B | EV / Sales 2023 * | 3,90x |
| Net cash position 2023 * | 5.43B | Net cash position 2024 * | 3.77B | EV / Sales 2024 * | 6,00x |
| P/E ratio 2023 * | -5,85x | P/E ratio 2024 * | -13,1x | Employees | 3,900 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 90.37% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.63% | ||
| 1 week | +1.30% | ||
| Current month | +1.30% | ||
| 1 month | +6.86% | ||
| 3 months | -27.36% | ||
| 6 months | -37.34% | ||
| Current year | -56.18% |
1 week
74.50
84.12
1 month
67.6284.12
Current year
62.55207.51
1 year
62.55217.25
3 years
62.55497.49
5 years
11.54497.49
10 years
11.54497.49
| Managers | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 50 | 2011 |
James Mock
DFI | Director of Finance/CFO | 46 | 2022 |
Stephen Hoge
PSD | President | 47 | 2012 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Paul Sagan
BRD | Director/Board Member | 64 | 2018 |
| Director/Board Member | 73 | 2020 | |
Francois Nader
BRD | Director/Board Member | 66 | 2019 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.10% | 5 M€ | -16.24% | ||
| 5.66% | 0 M€ | 0.00% | - | |
| 5.54% | 12 M€ | -19.81% | ||
| 4.69% | 2 M€ | 0.00% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-07 | 79.05 | -1.92% | 1 462 083 |
| 23-12-06 | 80.6 | +2.96% | 4,404,650 |
| 23-12-05 | 78.28 | -1.99% | 2,160,072 |
| 23-12-04 | 79.87 | +0.05% | 3,171,966 |
| 23-12-01 | 79.83 | +2.74% | 3,958,346 |
Delayed Quote Nasdaq, December 07, 2023 at 10:44 am EST
More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
08:00am
- Investor Day - ESG
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
80.6USD
Average target price
139.76USD
Spread / Average Target
+73.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -56.18% | 30 731 M $ | |
| +69.16% | 40 713 M $ | |
| +4.65% | 39 345 M $ | |
| -27.61% | 28 435 M $ | |
| +37.99% | 22 100 M $ | |
| -26.09% | 21 964 M $ | |
| -1.81% | 16 910 M $ | |
| -13.57% | 11 278 M $ | |
| -18.77% | 10 444 M $ | |
| -7.39% | 10 294 M $ |
